jakafi guid pipelin updat
messag report earn includ top bottom line
estim beat well guidanc top end street estim
pipelin remain track includ top-line data evalu topic
ruxolitinib atop dermat ii pdufa date pemigatinib may
iii data jakafi steroid-refractori chronic gvhd reiter
neutral rate continu believ current valuat catalyst
line-up offer balanc risk/reward profil share
top bottom line beat report revenu came
estim street consensu includ
jakafi sale estim contribut
jakafi sale slightli guidanc manag
confirm increas jakafi sale driven growth across approv
indic mf pv gvhd oper expens street estim
primarili driven increas expens pipelin progress later
stage develop overal report bottom line beat dilut
ep vs guggenheim street estim
guidanc upper end street expect announc guidanc
today call howev import note guidanc includ financi
impact recent announc deal morphosi mor-d guid toward
jakafi revenu vs consensu repres
growth sale manag also confirm expect gross-
to-net adjust jakafi addit guid toward
oper expens non- opex
impli continu margin expans
continu focu maintain leadership mpn confirm continu
advanc limber program corpor object maintain leadership
myeloprolif neoplasm beyond ruxolitinib progress date includ on-going
trial once-a-day formul ruxolitinib bioavailability/ bioequival data
track ii on-going combin trial jakafi jakafi pim data
track iii clear ind agent use combin jakafi
bet-inhibitor trial initi
pivot topic ruxolitinib program remain track alreadi announc
posit top-line data studi earlier year manag confirm
top-line data avail come week manag confirm
remain track file potenti nda topic ruxolitinib atop dermat
follow longer term safeti efficaci data true-ad program furthermor
confirm initi true-v data on-going pivot program topic
ruxolitinib vitiligo expect
pemigatinib review cholangiocarcinoma addit trial on-going recal
submit nda pemigatinib treatment
cholangiocarcinoma base studi link sinc grant
pdufa date may manag also confirm ema valid
mma seek approv pemigatinib europ pemigatinib also evalu
on-going studi ph ii studi bladder cancer expect
updat data per manag guidanc ph ii tumor-agnost
studi patient fgf/ fgfr driver-activ remain on-going
page analyst certif import disclosur
graft-versus-host diseas gvhd program continu progress recal
trial evalu jakafi steroid-refractori acut gvhd met primari endpoint
link random ph studi alreadi approv regimen ph ii
trial announc full dataset present part
presidenti symposium european societi blood marrow transplant
ebmt held march per abstract jakafi rel best avail therapi
demonstr higher orr day vs higher cr rate vs
orr day vs meanwhil ph trial evalu jakafi
steroid-refractori chronic gvhd remain on-going data expect read
per manag guidanc addit continu progress
trial evalu itacitinib patient newli diagnos chronic gvhd recal earlier
year announc ph random trial evalu itacitinib
steroid-nav acut gvhd meet primari endpoint day orr link
addit upcom data updat ph ii data parsaclisib nhl ph ii
data anal cancer initi data solid tumor
reiter neutral rate recent downgrad see preview
follow stock run vs btk think current valuat
catalyst line-up offer balanc risk/reward profil stock
maintain neutral rate
model updat reflect quarter updat model reflect quarterli trend
well corpor guidanc specif increas jakafi estim decreas
page analyst certif import disclosur
rate neutral valu share use probabl adjust free cash flow project
jakafi iclusig olumi capmatinib topic ruxolitinib use discount rate
consist commerci stage biotech compani coverag termin growth
rate
 regulatori commerci setback
potenti emerg new competitor
dilut financ beyond assum
pipelin success beyond alreadi account model
higher product sale current model
page analyst certif import disclosur
chang fair valu acquisition-rel conting consideration-
interest incom net
unreal gains-to-loss long-term invest
incom tax
balanc sheet statement flow
compani report guggenheim secur llc estim
page analyst certif import disclosur
